Quick Take: MindMed announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The results of this study indicate that pharmacogenetic testing prior to LSD-assisted treatment may inform LSD dose selection at the individual patient level. MindMed (Nasdaq: MNMD), a leading psychedelic medicine biotech company, announced today the publication of the…